About Genoptix
Genoptix is a company based in Carlsbad (United States) founded in 1999 by Tina S Nova and Gene Tu was acquired by NeoGenomics in October 2018. Genoptix has raised $33.26 million across 7 funding rounds from investors including Novartis, Comerica and NeoGenomics. The company has 46 employees as of December 31, 2018. Genoptix has completed 2 acquisitions, including HistoRx and Rosetta Genomics. Genoptix operates in a competitive market with competitors including Abingdon Health, Precipio Diagnostics, SkylineDX, Elucida Oncology and JaxBio, among others.
- Headquarter Carlsbad, United States
- Employees 46 as on 31 Dec, 2018
- Founders Tina S Nova, Gene Tu
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genoptix, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$33.26 M (USD)
in 7 rounds
-
Latest Funding Round
$17.3 M (USD), Series D
Aug 10, 2005
-
Investors
Novartis
& 6 more
-
Employee Count
46
as on Dec 31, 2018
-
Investments & Acquisitions
HistoRx
& 1 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Genoptix
Genoptix has successfully raised a total of $33.26M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $17.3 million completed in August 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genoptix
Genoptix has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Comerica and NeoGenomics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Healthcare investments are made by Tullis Health Investors.
|
Locked | Locked | Locked | |
|
Expansion and growth capital is provided by 1315 Capital to healthcare companies.
|
Locked | Locked | Locked |
Investor details for Genoptix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genoptix
Genoptix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include HistoRx and Rosetta Genomics.
Investment portfolio details for Genoptix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Tissue-based diagnostic solutions for research and clinical pathology markets
|
Locked | Locked | 2001 | Locked | |
|
Genetic tests for cancer diagnosis and profiling are developed.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Genoptix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Genoptix
Detailed financials for Genoptix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genoptix Comparisons
Peer comparison for Genoptix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genoptix
Genoptix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Precipio Diagnostics, SkylineDX, Elucida Oncology and JaxBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of immunoassays for diagnostic purposes
|
|
| Locked | Locked | Locked |
Cancer diagnostics and second opinion tools are offered.
|
|
| Locked | Locked | Locked |
Gene expression profiling tests are provided for personalized medicine.
|
|
| Locked | Locked | Locked |
Nanotechnology-based particle delivery platform is developed for oncology applications.
|
|
| Locked | Locked | Locked |
Developer of an AI-based chip for genetic and epigenetic profiling
|
Detailed competitors of Genoptix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genoptix
Complete news archive for Genoptix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genoptix
Genoptix was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Genoptix is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Joseph Limber is the current CEO of Genoptix.
Genoptix is a funded company, having raised a total of $33.26M across 7 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Genoptix is 46.
Genoptix focussed on Oncology diagnostics and informatics services. It was the first licensee of AQUA technology (which it received by acquiring HistoRx) to perform clinical laboratory services for measurement of protein in tissue specimens. It has launched a series of breast cancer assays using this platform. It also provides comprehensive testing solutions to community oncologists and pathologists in hematology and solid tumor molecular profiling. It claims that it has the largest hematopathology center in US and is specialized in diagnosing cancers in bone marrow, blood and lymph nodes. It was acquired by Novartis in January 2011 for 470M and is currently serving as its subsidiary.
Genoptix's top competitors include Abingdon Health, Precipio Diagnostics and SkylineDX.
Genoptix has made 2 acquisitions, including HistoRx, and Rosetta Genomics.
Genoptix has 7 investors. Key investors include Novartis, Comerica, NeoGenomics, Chicago Growth Partners, and Tullis Health Investors.